Nectar Lifesciences Ltd Stock Analysis

BSE: 532649 | NSE: NECLIFE | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 25-Nov-2022 18:01
21.10 1.00 (4.98%)

DeciZen - Make an Informed Decision on Nectar Lifesciences

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation

Somewhat Undervalued

3. Price Trend

Nectar Lifesciences Price Chart

P/E Ratio (SA) :
165.57
Market Cap :
473.2 Cr.
52-wk low :
19.5
52-wk high :
39
Bole Toh?

1. Is Nectar Lifesciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Nectar Lifesciences Ltd is a average quality company.

2. Is Nectar Lifesciences Ltd undervalued or overvalued?

The key valuation ratios of Nectar Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Nectar Lifesciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Nectar Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Nectar Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Nectar Lifesciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % 9.3%9%8.4%7.4%7.2%6.8%7.5%6%1.2%3.8%-
Value Creation Index -0.3-0.4-0.4-0.5-0.5-0.5-0.5-0.6-0.9-0.7-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,6261,6381,6441,6761,6431,8762,7852,3631,5421,6681,711
YoY Gr. Rt. %-0.7%0.3%2%-2%14.1%48.5%-15.2%-34.8%8.2%-
Adj EPS 3.82.832.42.42.32.11.3-2.50.80.1
YoY Gr. Rt. %--27.5%6.5%-17.6%-0.4%-3.7%-9%-37.3%-285.7%NA-
BVPS (₹) 38.741.341.142.644.947.249.350.647.348.547.6
Adj Net Profit 85.762.166.254.454.352.247.529.9-55.418.73
Cash Flow from Ops. 36125514416919965.123928621.395-
Debt/CF from Ops. 2.43.46.45.74.414.73.82.742.49.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 0.3%0.3%-15.7%8.2%
Adj EPS -15.5%-19.1%-26.6%NA
BVPS 2.51.5-0.52.5
Share Price 0.5% -8.5% 17.6% -15.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % 10.46.975.75.55.14.42.7-51.70.3
Op. Profit Mgn % 17.817.616.214.313.612.69.59.26.69.57.6
Net Profit Mgn % 5.33.843.33.32.81.71.3-3.61.10.2
Debt to Equity 10.9110.90.90.80.70.90.80.2
Working Cap Days 251270285298324292206240330288295
Cash Conv. Cycle 13312513414215313310411513210877

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 0.30%

Debt to equity has declined versus last 3 years average to 0.79

Sales growth is good in last 4 quarters at 16.28%

Sales growth has been subdued in last 3 years -15.70%

Net Profit has been subdued in last 3 years -26.55%

Latest Financials - Nectar Lifesciences Ltd.

Standalone Consolidated
TTM EPS (₹) 0.1 0.1
TTM Sales (₹ Cr.) 1,711 1,711
BVPS (₹.) 47.6 47.7
Reserves (₹ Cr.) 1,046 1,047
P/BV 0.44 0.44
PE 165.57 167.92
From the Market
52 Week Low / High (₹) 19.50 / 38.95
All Time Low / High (₹) 7.20 / 60.90
Market Cap (₹ Cr.) 473
Equity (₹ Cr.) 22.4
Face Value (₹) 1
Industry PE 37.3

Management X-Ray of Nectar Lifesciences :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.00100.00100.00100.00100.00100.00100.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Nectar Lifesciences

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Nectar Lifesciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Nectar Lifesciences on 25-Nov-2022 18:01 is : 21.10.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 25-Nov-2022 18:01 the market cap of Nectar Lifesciences stood at ₹ 473.2.
The latest PE ratio of Nectar Lifesciences as of 25-Nov-2022 18:01 is 165.6.
The latest PB ratio of Nectar Lifesciences as of 25-Nov-2022 18:01 is 0.44
The 52-week high of Nectar Lifesciences is ₹ 38.95 and the 52-week low is ₹ 19.50.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Nectar Lifesciences is ₹ 1,711 ( Cr.) .

About Nectar Lifesciences Ltd

Nectar Lifesciences Ltd. (NLL) is a knowledge driven organization which constitutes a vital part of fast growing Indian Pharmaceutical Industry. It has emerged as top ranked organization amongst midsized Pharmaceutical companies in India as per “Fortune Next 500” 2017 & is  among top 40 fore runners of the Bio-Pharmaceutical industry in Asia-Pacific Region as per “Bio-Spectrum Asia Pacific” 2016 besides being one of the top amongst Indian API manufacturers.

The company has transformed itself from being a small Domestic API player to one of the most integrated player in the Global Cephalosporins Industry within Anti Infective Therapeutic segment. It currently has a strong hold of API & Formulation business in many countries of the world with various State of Art manufacturing facilities spread across the States of Punjab and Himachal Pradesh with compliance to global standards of cGMP, Environment Health Safety (EHS) as well as pool of thousands of highly skilled, knowledgeable, competent qualified work force at all levels.

Business area of the company

The company has developed fully integrated sustainable production systems to manufacture high quality Cephalosporin intermediates, - Active Pharmaceuticals ingredients (APIs) and Finished Dosage Formulations (FDF or Formulations) to meet the diverse requirements of its customer base in India and over many countries worldwide.

Business segments

  • APIs
  • Formulations
  • Empty hard Gelatin Capsules
  • Phytochemicals

Certifications

  • GMP (Issued by World Health Organization - COPP)
  • ISO 9001:2008 - Quality Management
  • ISO 22000:2005 - Food Safety Management
  • ISO 14001: 2004 - Environment Management Systems
  • ISO 50001: 2011 - Energy Management System
  • OHSAS 18001: 2007 - Occupational Health and Safety
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now